AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor β (TGFβ) activation via multiple undisclosed targets.

Morphic is responsible for R&D through IND-enabling studies for each potential product, at which point AbbVie may pay an undisclosed license fee to exercise its option to gain worldwide development and commercialization rights to that product...